Ramy Riad: Advancing Plasma-Derived Therapies Through Partnership
Ramy Riad, President of Plasma-Derived Therapies Business Unit at Takeda, shared a post on LinkedIn:
“Wrapping up a productive first day at IPPC 2026, hosted by Plasma Protein Therapeutics Association (PPTA), with a real sense of momentum.
This year’s theme — ‘Resilience, Reach and Responsibility’ — perfectly captures the leadership imperative facing our industry.
No single organization can sustain the plasma ecosystem alone.
It requires long‑term partnerships and shared responsibility across the value chain.
Today’s conversations reinforced how essential collaboration is to protect access for the patients who depend on plasma-derived therapies.
Looking forward to the sessions ahead and to connecting with fellow leaders shaping the future of plasma.”
Stay updated with Hemostasis Today.
-
Jun 27, 2026, 18:19Nabil Tabish: The Paradox of Zero – Investigating Extreme VWF Discordance
-
Jun 27, 2026, 18:19Francesco Favruzzo: Can Mechanical Thrombectomy Be Safely Used in Cervical Artery Dissection?
-
Jun 27, 2026, 18:18Vera Ghali: 2026 ASH–ISTH Recommendations on Pediatric VTE Prevention
-
Jun 27, 2026, 18:17Michiel Coppens: A Hemostasis Laboratory – One of the Cornerstones of Our Hemophilia Mission
-
Jun 27, 2026, 18:16Sthanu Subramanian: Dabigatran and Mechanical Heart Valves
-
Jun 27, 2026, 15:50Muhammet Özbilen: The Skin as an Emerging Regulator of Iron Homeostasis
-
Jun 27, 2026, 15:07Anteneh Berhane: Supporting Healthier Pregnancies Through Early Nutrition
-
Jun 27, 2026, 14:35Mobina Nakhaei: Why Alloantibodies Develop Despite ABO/Rh Matching in Thalassemia
-
Jun 27, 2026, 14:01Abdul Mannan: DOACs in Cancer-Associated VTE – When to Avoid Them, And When LMWH Wins